Acadia Pharmaceuticals Inc (ACAD) 19.44 $ACAD
Acadia Pharmaceuticals Has Returned 21.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Apr 16, 9:37AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 3 weeks, Acadia Pharmaceuticals has returned 21.34% as of today's recent price of $18.67.
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
SmarTrend Watching for Potential Rebound in Shares of Acadia Pharmaceuticals After 6.41% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:11PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $16.95 to a high of $19.71. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $18.50 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 11.5% (ACAD)
Comtex SmarTrend(R) - Wed Apr 09, 9:21AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 weeks, Acadia Pharmaceuticals has returned 11.48% as of today's recent price of $21.01.
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
Business Wire - Tue Apr 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City.
aTyr Pharma Appoints David M. Weiner, M.D., as Chief Medical Officer
PR Newswire - Fri Mar 28, 7:00AM CDT
aTyr Pharma ("aTyr"
, a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders.
Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
14.2% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Wed Mar 19, 9:26AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.21% as of today's recent price of $28.42.
Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACADIA Pharmaceuticals prices public offering of 6.4m common shares
M2 - Wed Mar 05, 4:24AM CST
Biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) said on Tuesday that it has priced a public offering of 6,400,000 shares of its common stock.
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Mar 04, 6:28PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 960,000 shares of common stock. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.
ACADIA Pharmaceuticals plans to issue common stock in public offering
M2 - Tue Mar 04, 5:05AM CST
US-based biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) revealed on Monday that it intends to offer and sell USD150m of shares of its common stock in a public offering.
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Acadia Pharmaceuticals Shares Up 12.4% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Mon Mar 03, 10:02AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 12.44% as of today's recent price of $27.98.
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 10:55AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Business Wire - Thu Feb 27, 3:02PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Critical Alerts For Microsoft, GlaxoSmithKline, SunEdison, Acadia, and Family Dollar Released By InvestorsObserver
PR Newswire - Thu Feb 27, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MSFT, GSK, SUNE, ACAD, and FDO.
Acadia Pharmaceuticals Has Returned 21.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Apr 16, 9:37AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 3 weeks, Acadia Pharmaceuticals has returned 21.34% as of today's recent price of $18.67.
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
SmarTrend Watching for Potential Rebound in Shares of Acadia Pharmaceuticals After 6.41% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:11PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $16.95 to a high of $19.71. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $18.50 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 11.5% (ACAD)
Comtex SmarTrend(R) - Wed Apr 09, 9:21AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 weeks, Acadia Pharmaceuticals has returned 11.48% as of today's recent price of $21.01.
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
Business Wire - Tue Apr 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City.
aTyr Pharma Appoints David M. Weiner, M.D., as Chief Medical Officer
PR Newswire - Fri Mar 28, 7:00AM CDT
aTyr Pharma ("aTyr"
, a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders. Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
14.2% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Wed Mar 19, 9:26AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.21% as of today's recent price of $28.42.
Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACADIA Pharmaceuticals prices public offering of 6.4m common shares
M2 - Wed Mar 05, 4:24AM CST
Biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) said on Tuesday that it has priced a public offering of 6,400,000 shares of its common stock.
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Mar 04, 6:28PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 960,000 shares of common stock. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.
ACADIA Pharmaceuticals plans to issue common stock in public offering
M2 - Tue Mar 04, 5:05AM CST
US-based biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) revealed on Monday that it intends to offer and sell USD150m of shares of its common stock in a public offering.
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Acadia Pharmaceuticals Shares Up 12.4% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Mon Mar 03, 10:02AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 12.44% as of today's recent price of $27.98.
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 10:55AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Business Wire - Thu Feb 27, 3:02PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Critical Alerts For Microsoft, GlaxoSmithKline, SunEdison, Acadia, and Family Dollar Released By InvestorsObserver
PR Newswire - Thu Feb 27, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MSFT, GSK, SUNE, ACAD, and FDO.
